Gastrointestinal Stromal Tumors of the Stomach
Top Cited Papers
- 1 January 2005
- journal article
- Published by Wolters Kluwer Health in The American Journal of Surgical Pathology
- Vol. 29 (1) , 52-68
- https://doi.org/10.1097/01.pas.0000146010.92933.de
Abstract
Gastrointestinal (GI) stromal tumors (GISTs), the specific KIT- or PDFGRA-signaling driven mesenchymal tumors, are the most common mesenchymal tumors of the GI tract. In this study, we analyzed 1869 cases originally classified as smooth muscle tumors of the stomach and found that 1765 (94%) of these were GISTs. The GISTs had a slight male predominance (55%) with a median age of 63 years. Only 2.7% of tumors occurred before the age of 21 years and 9.1% before the age of 40 years. The tumors varied from 0.5 to 44 cm (median, 6.0 cm) and most commonly presented with GI bleeding; 12% were incidentally detected. Several histologic variants were recognized among the spindle cell tumors (sclerosing, palisaded-vacuolated, hypercellular, and sarcomatous) and of epithelioid tumors (sclerosing, dyscohesive, hypercellular, and sarcomatous). Outcome was strongly dependent on tumor size and mitotic activity. Only 2% to 3% of tumors 10 cm and >5 mitoses/50 HPFs metastasized. However, tumors >10 cm with mitotic activity 5/50 HPFs had a relatively low metastatic rate (11% and 15%). A small number of patients survived intra-abdominal metastasis up to over 20 years. Tumor location in fundus or gastroesophageal junction, coagulative necrosis, ulceration, and mucosal invasion were unfavorable factors (P <0.001), whereas tumor location in antrum was favorable (P <0.001). KIT expression was detected in 91% of the cases, CD34 in 82%, smooth muscle actin in 18%, and desmin in 5%; the latter two were favorable (P <0.001). KIT exon 11 mutations were detected in 119 cases; patients with point mutations fared better than those with deletions (P <0.01). PDGFRA exon 18 mutations (total 86 cases) were common in epithelioid GISTs and most commonly represented a D842V point mutation; none of these was prognostically significant. The above results may be helpful for setting the criteria for adjuvant treatment such as Gleevec.Keywords
This publication has 23 references indexed in Scilit:
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triadAmerican Journal of Medical Genetics, 2002
- Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumoursThe Journal of Pathology, 2001
- Two Hundred Gastrointestinal Stromal TumorsAnnals of Surgery, 2000
- Gastric Stromal Sarcoma, Pulmonary Chondroma, and Extra-adrenal Paraganglioma (Carney Triad): Natural History, Adrenocortical Component, and Possible Familial OccurrenceMayo Clinic Proceedings, 1999
- Prognosis of Gastrointestinal Smooth-Muscle (Stromal) TumorsThe American Journal of Surgical Pathology, 1999
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 yearsCancer, 1985
- Gastric epithelioid leiomyoma and leiomyosarcoma (leiomyoblastoma)Cancer, 1976